The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide and crystalline forms of salts and/or solvates of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carbox ylic acid (5-methyl-pyrazin-2-ylmethyl)-amide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms and the compositions thereof.本發明包括2-(4-甲基-[1,4]二氮雜環庚烷-1-基)-5-氧代-5H-7-硫雜1,11b二氮雜-苯並[c]芴-6-羧酸(5-甲基-吡啶-2-基甲基)-胺化物的結晶形式,及2-(4-甲基-[1,4]二氮雜環庚烷-1-基)-5-氧代-5H-7-硫雜1,11b二氮雜-苯並[c]芴-6-羧酸(5-甲基-吡啶-2-基甲基)-胺化物的鹽及/或溶劑合物之結晶形式。此外,本發明提供包含所述結晶形式的組合物,以及所述結晶形式的治療用途及其組合物。
